Type of information: Grant
Company: Oryzon Genomics (Spain)
Investors: Alzheimer’s Drug Discovery Foundation (ADDF) (USA - NY)
Funding type: grant
- This grant will support the project “Clinical development of a companion marker for treatment with the dual LSD1/MAO-B inhibitor ORY-2001“. ORY-2001 is a highly selective dual LSD1-MAOB inhibitor that is pioneering the histone demethylases
field in neurodegenerative disorders. The molecule restores cognitive function and memory loss in nontransgenic Alzeheimer's disease mouse models and changes gene expression on the hippocampus, increasing memory-related genes and decreasing neuroinflammation genes.
- Oryzon is finishing an ongoing double-blind, placebo-controlled Phase 1 clinical trial in healthy volunteers of its proprietary oral LSD1- MAOB dual selective inhibitor ORY-2001. The company recently presented top line data from this clinical trial in the ADPD meeting in Vienna in March and is confident to start in the near future several Phase IIs with ORY-2001 in neurodegenerative disorders including Alzheimer’s disease.
The ADDF will supply funds to develop assays and perform a biomarker study as part of a clinical trial with ORY-2001.
Others: • On April 24, 2017, Oryzon Genomics announced that the Board of Directors of the Alzheimer’s Drug Discovery Foundation (ADDF) has approved a grant of $300,000 t support the project “Clinical development of a companion marker for treatment with the dual LSD1/MAO-B inhibitor ORY-2001.” Under the terms of the grant, the ADDF has received 82,029 ordinary shares of the Company, at a price of € 3.410 per share (par value € 0.05 each) representing 0.24% of the capital.
Therapeutic area: Neurodegenerative diseases